Black Mold and Bogus Records: What the FDA's 2026 Chinese GLP-1 Ingredient Inspections Mean for Compounded Semaglutide and Tirzepatide

The two facilities make active pharmaceutical ingredients (API) — the raw semaglutide and tirzepatide powder that compounding pharmacies turn into finished injections.

At Chengdu Shengnuo Biopharm, inspected in August 2026, investigators documented black mold on equipment, "gross contamination" on the floors, and what the reports described as significant insect activity in the ceilings. More troubling than the housekeeping: as inspectors arrived, quality staff reportedly moved laboratory records into a nearby room and into lockers, and personnel dumped product samples down sinks in what appeared to be a coordinated effort. Not all of the documents were recovered.

At Nanjing Chengong Pharmaceutical, inspected in September 2026, the problem was different but arguably worse for patients: workers purchased active ingredients made by other manufacturers and applied their own company's approval seal — without verifying the original makers' testing data. In plain terms, the label on the drum did not tell you who actually made the powder inside, or whether anyone had confirmed it was what it claimed to be.

Michael Rogers, a former FDA associate commissioner for inspections, told Bloomberg the findings "suggest a serious accident waiting to happen." Chengdu Shengnuo, for its part, said in a Chinese regulatory filing that it has been "diligently implementing effective measures" to fix the problems.

Both companies were added to the FDA's import alert list, the agency's standard tool for foreign facilities that fail inspection. An import alert lets US Customs and FDA detain the company's shipments at the border without physically examining them — effectively cutting the facility off from the US market until it demonstrates compliance.

That is meaningful protection going forward, but it is not retroactive. Ingredients that already entered the country before the alert are not recalled by it, and the FDA has not announced a recall of any finished compounded product in connection with these inspections. There is also no public evidence at this point tying these two facilities to specific US pharmacies or to any patient harm.

A Brookings Institution analysis cited in the coverage notes that a substantial portion of the ingredients behind US compounded GLP-1 drugs originates in China. That is not inherently a problem — much of the global API supply for many common medications is made there, including for brand-name drugs, under facilities that pass FDA inspection. The problem is variability. Brand-name Wegovy and Zepbound are made end-to-end inside Novo Nordisk's and Eli Lilly's audited supply chains. Compounded versions depend on each pharmacy's choices: which API supplier it buys from, whether that supplier is FDA-registered and inspected, and whether the pharmacy independently tests what arrives.

The official shortages of semaglutide and tirzepatide ended in 2025, which narrowed the legal lane for compounding — it now generally requires a clinical reason, such as a personalized dose, rather than mere unavailability. That shift pushed some of the demand toward exactly the wrong places: unregulated "research peptide" websites and gray-market sellers with no pharmacy license at all, a market we covered in our warning about black-market retatrutide. This week's inspection findings land hardest there, because gray-market sellers are precisely the buyers least likely to audit a supplier or reject a drum of powder with a questionable seal.

None of this means patients need to abandon compounded treatment — it means sourcing questions are fair game, and a legitimate provider will answer them readily. Worth asking: Is the pharmacy licensed in your state, and is it a 503A pharmacy dispensing against your individual prescription (or a 503B outsourcing facility)? Does it buy API only from FDA-registered manufacturers, and can it provide a certificate of analysis showing identity and purity testing for each batch? Does a licensed provider review your health history and labs before prescribing, and adjust your dose over time?

If a seller requires no prescription, will not name its pharmacy, or ships vials labeled "for research use only," that is not compounding — that is the gray market, and these inspection reports are a picture of what can sit upstream of it. Our deeper guide to compounded semaglutide safety walks through the regulatory details.

Whatever the source, GLP-1 medications are prescription drugs with real side effects — commonly nausea, vomiting, constipation, and diarrhea, and rarely pancreatitis or gallbladder problems. They are not appropriate for people with a personal or family history of medullary thyroid carcinoma or MEN 2, and the decision to start, switch, or stop should always be made with a licensed provider who knows your history.

JoeyMed was built around the transparency this story demands. Every weight loss treatment plan starts with an online health assessment reviewed by a licensed provider, and medications — including TIRZ HD, our high-dose tirzepatide program — are dispensed through state-licensed US pharmacies with verified, tested ingredient sourcing, never gray-market suppliers. If nausea is a concern as you titrate, anti-nausea support can be added to your plan. Start the assessment today, ask us the sourcing questions above, and make the decision with a provider — not a headline — guiding you.